Why is ANG Lifesciences falling/rising?

As of 27-Jun, ANG Lifesciences India Ltd is currently priced at 28.00, reflecting an increase of 0.17 or 0.61%. The stock has been gaining for the last two days, with a total return of 1.23% during this period. However, it is important to note that the stock has consistently underperformed against the benchmark, with a year-to-date decline of 37.35% compared to a 7.58% increase in the Sensex. The company is facing significant challenges, including operating losses and a high Debt to EBITDA ratio of 5.83 times, which indicates a low ability to service its debt. Additionally, the company has reported negative results for the last 12 consecutive quarters, contributing to its negative return on equity and overall weak long-term fundamental strength.
In the broader market context, while ANG Lifesciences has shown a slight uptick in price recently, it has still underperformed the Sensex over various time frames, including a 1-week decline of 1.96% compared to a 2.00% increase in the benchmark. The stock's performance is further hindered by the fact that 44.88% of promoter shares are pledged, which can exert additional downward pressure in a falling market. Despite a recent rise in investor participation, as indicated by a 25.7% increase in delivery volume, the overall sentiment remains cautious due to the company's ongoing financial struggles and consistent underperformance against the benchmark over the last three years.